Circulation
January 7, 2014 discriminatory in intermediate-risk individuals, 8, 9 and appears superior to other novel risk markers. 9 Accordingly, current guidelines assign a class IIa recommendation for CAC measurement in asymptomatic intermediate-risk patients (10-20% 10-year risk) and a class IIb recommendation in low-to intermediate-risk patients (6-10% 10-year risk). 10 However, CAC measurement is not currently incorporated into treatment algorithms in dyslipidemia guidelines in the United States or abroad. [1] [2] [3] [4] When one considers its potential role in such algorithms, the following question arises: How well does CAC stratify risk across dyslipidemia categories? Therefore, we sought to evaluate the interplay between CAC and dyslipidemia in relation to CVD outcomes in the Multi-Ethnic Study of Atherosclerosis (MESA). We hypothesized that (1) many subjects with dyslipidemia would have no CAC and vice versa and (2) CAC would consistently stratify CVD risk across categories of dyslipidemia.
Methods

Study Participants
Details on the prospective design and organization of MESA are available in previous reports. 6, 11 From July 2000 to September 2002, 6814 adults from the general community were enrolled at 6 field centers in the United States (Baltimore, MD; Chicago, IL; Forsyth County, NC; Los Angeles, CA; New York, NY; and St Paul, MN). Participants were aged 45 to 84 years at enrollment, were free of clinical CVD, and identified themselves as white, black, Hispanic, or Chinese. The study was approved by the institutional review boards at each site, and all participants provided written informed consent.
For the purposes of the present study, 1194 participants (18%) who were on baseline dyslipidemia medications were excluded ( Figure 1 ). Dyslipidemia medications were statins, niacin, fibrates, ezetimibe, bile acid sequestrants, or fish oil. Of the remaining 5620 participants, 86 had missing lipid data and were excluded. The resulting study population consisted of 5534 MESA participants.
CAC Measurements
Details on the MESA methods for computed tomographic (CT) scanning and interpretation have been published. 12 At baseline, each center performed CAC scanning with either a cardiac-gated electronbeam CT scanner (Chicago, Los Angeles, New York) or a multidetector CT system (Baltimore, Forsyth County, St Paul) by a standardized protocol with the use of calcium phantoms to facilitate image calibration. Patients were scanned twice, and images were interpreted at the MESA CT reading center (Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles Medical Center, Torrance, CA).
The CAC score was determined by the Agatston method, 13 and the mean of the 2 scores was used in all analyses. Intraobserver and interobserver agreements were high (κ=0.93 and κ=0.90, respectively). 6 Participants were told either that they had no coronary calcification or that the amount was less than average, average, or greater than average and that they should discuss the results with their physicians.
Lipid Measurements
At baseline, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglyceride measurements were performed at the Collaborative Studies Clinical Laboratory at Fairview-University Medical Center (Minneapolis, MN) in blood samples obtained after a 12-hour fast. Total cholesterol was measured from plasma with the use of a cholesterol oxidase method (Roche Diagnostics, Indianapolis, IN) on a Roche COBAS FARA centrifugal analyzer. The laboratory coefficient of variation was 1.6%. HDL-C was measured in EDTA plasma with the use of the cholesterol oxidase method (Roche Diagnostics, Indianapolis, IN) after precipitation of non-HDL-C with magnesium/ dextran (coefficient of variation, 2.9%). Triglycerides were measured in EDTA plasma with the use of triglyceride GB reagent (Roche Diagnostics, Indianapolis, IN) on a Roche COBAS FARA centrifugal analyzer (coefficient of variation, 4.0%).
LDL-C was estimated by the Friedewald equation if triglycerides were <4.52 mmol/L (400 mg/dL).
14 Non-HDL-C was calculated as TC minus HDL-C. LDL particle number was measured by nuclear magnetic resonance spectroscopy with the use of the commercially available LipoProfile-II spectral analysis process (LipoScience, Raleigh, NC) (coefficient of variation, <4%).
Nonlipid Risk Factors
At baseline, resting blood pressure was measured 3 times with a Dinamap Pro 1000 automated oscillometric sphygmomanometer (Critikon); the mean of the last 2 readings was used. Hypertension was defined by criteria of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure or history of antihypertensive therapy. Diabetes mellitus was defined as either the presence of a fasting plasma glucose level ≥7.00 mmol/L (126 mg/dL) or a history of treatment with diabetes mellitus medications. Participants were categorized as current cigarette smokers, former smokers, or persons who had never smoked on the basis of self-report. A family history of CHD was considered present if any immediate family member had suffered a myocardial infarction or undergone coronary revascularization. Socioeconomic status was defined by level of education.
Ascertainment of Incident CVD
Every 9 to 12 months, through May 2011, trained personnel called to inquire about hospital admissions, outpatient diagnoses of CVD, or deaths. Follow-up telephone interviews were completed in 92% of living participants. Medical records were obtained for 98% of hospital admissions and 95% of outpatient diagnoses. For reported out-of-hospital deaths, the next of kin were interviewed, and copies of death certificates were requested. CVD events were adjudicated by a MESA committee of cardiologists, physician epidemiologists, and neurologists.
Our main outcome measure was CVD because it is the focus of the latest prevention guidelines and because statin therapy reduces the risk of both coronary and cerebrovascular events. [3] [4] [5] [15] [16] [17] CVD events included myocardial infarction, angina resulting in revascularization, resuscitated cardiac arrest, stroke, or cardiovascular death. Because knowledge of the CAC score might have affected the ascertainment and management of angina resulting in revascularization, we conducted a sensitivity analysis of "hard CVD" events in which we excluded angina resulting in revascularization. Additional details on follow-up methods and event adjudication are available on the MESA Web site (http://www.mesa-nhlbi.org).
Statistical Analysis
The CAC score was examined as a binary variable (presence or absence) and as a categorical variable (0, 1-99, ≥100).
18 Participants Figure 1 . 19 reflects the way that many clinicians and patients think about an increasing burden of dyslipidemia from a clinical standpoint. We prioritized this scheme in analyses given its simplicity and conceptual similarity to risk factor counting, as used in clinical practice guidelines. 1, 2 In parallel with these analyses, we present results in which dyslipidemia in classified by TC/HDL-C quartiles.
Baseline characteristics were analyzed by number of LA. We calculated proportions for categorical variables and mean±SD values for We used an unadjusted Kaplan-Meier failure function to describe the occurrence of CVD events over time across strata of CAC and LA or TC/HDL-C quartiles. Next we compared absolute CVD event rates and Cox multivariable-adjusted hazard ratios for CAC categories by LA or TC/HDL-C quartiles. There were no violations of the proportional hazards assumption by Schoenfeld residuals.
We performed hierarchical multivariable modeling in which model 1 was unadjusted; model 2 was adjusted for age, sex, ethnicity, education, and MESA site; and model 3 was adjusted for model 2 variables plus hypertension, diabetes mellitus, smoking, body mass index, and family history. We tested for interaction between dyslipidemia and CAC, dyslipidemia and sex, and dyslipidemia and ethnicity.
We further examined CVD event rates by CAC and guideline categories of LDL-C or non-HDL-C and data set quartiles of LDL-C, non-HDL-C, or LDL particle concentration. We also conducted 3 sensitivity analyses of the multivariable Cox model, as follows: (1) adding adjustment for dyslipidemia medication initiation during follow-up; (2) excluding those initiating dyslipidemia medications during follow-up; and (3) including those taking dyslipidemia medications at any time.
All analyses were performed with Stata software version 11.0 (StataCorp, College Station, TX). We considered a 2-tailed P value of <0.05 nominally significant. This data analysis plan was peer reviewed and approved by the MESA Publications and Presentations Committee. A complete copy of the a priori statistical analysis plan 20 is available on request. Table 1 shows baseline characteristics of the study cohort by LA burden. There were 1975 participants (36%) with 0 LA, 2021 (37%) with 1 LA, 1208 (22%) with 2 LA, and 330 (6%) with 3 LA. Age was modestly lower in participants with 3 LA (60.3±10.0) than in those with 0 LA (62.0±10.7). The burden of multiple other CVD risk factors and the Framingham Risk Score generally increased as the number of LA increased.
Results
Study Population by LA
CAC Distribution by Dyslipidemia Categories
As shown in Figure 2A , more than half of individuals with no LA had CAC=0 (58%), whereas those with increasing LA were less likely to demonstrate CAC=0 (P<0.0001). CAC scores of 1 to 99 and ≥100 were seen in 22% and 20% of individuals with no LA. In comparison, the respective prevalence was 29% and 21% among those with 3 LA. Similar results were seen when dyslipidemia was categorized by TC/HDL-C quartiles ( Figure 2B ).
CVD Events
Overall, 353 CVD events (6%) occurred during 7.6 years of median follow-up. Those with any CAC accounted for 288 events (82%). More than half of events (194; 55%) occurred in the 1155 participants (21%) with CAC ≥100. Conversely, 65% of events occurred in participants with 0 or 1 LA.
The CVD rate was 7.1 per 1000 person-years (95% confidence interval [CI], 5.8-8.7) for those with no LA compared with 9.3 (95% CI, 7.8-11.0), 11.6 (95% CI, 9.5-14.2), and 13.9 (95% CI, 9.8-19.8) per 1000 person-years among those with 1, 2, and 3 LA, respectively. Overall, 2.2%, 6.7%, and 16.8% absolute CVD events were seen in those with CAC=0, CAC=1 to 99, and CAC ≥100, respectively. During study follow-up, the corresponding CVD event rates were 3.0 per 1000 person-years (95% CI, 2.4-3.9) for those with CAC=0 compared with 9.8 (95% CI, 8.0-12.0) and 26.5 (95% CI, 23.0-30.5) per 1000 person-years among those with CAC scores of 1 to 99 and ≥100, respectively. Figure 3 shows increased cumulative incidence of CVD by CAC score among individuals stratified by the number of LA ( Figure 3A) or TC/HDL-C ( Figure 3B ). Figure 4 shows that the lowest event rate was observed in those with no CAC and no LA (or in the lowest TC/HDL-C quartile), whereas those with CAC ≥100 and 3 LA (or in the highest TC/HDL-C quartile) had the highest CVD event rate. Of note, individuals with no LA and CAC ≥100 had a higher event rate compared with individuals with 3 LA but CAC=0 (22.7 versus 5.9 per 1000 person-years). Similar results were obtained with the use of guideline categories of LDL-C or non-HDL-C ( Figure 5 ) and data set quartiles of Friedewald LDL-C, non-HDL-C, or LDL particle concentration ( Figure I in the online-only Data Supplement). Table 2 shows unadjusted and incrementally adjusted hazard ratios for CVD events associated with the presence of CAC and CAC ≥100 stratified by dyslipidemia burden. Compared with CAC=0, CAC ≥100 was associated with a significant 3-to 6-fold increased risk of CVD across the spectrum of dyslipidemia. There was no interaction between dyslipidemia and CAC, dyslipidemia and sex, or dyslipidemia and ethnicity. Risk associated with CAC was mostly insensitive to adjustment for baseline and follow-up dyslipidemia medications (Table I in Among those with CAC=0 at baseline (n=2977), the respective median 7.6-year CVD-free survival was 98.1%, 97.9%, 96.7%, and 95.3% in those with 0, 1, 2, and 3 LA, respectively ( Figure II in the online-only Data Supplement). In age-, sex-, and risk factor-adjusted Cox regression analyses, increasing LA were associated with higher hazard ratios for CVD across CAC score categories (Table II in 
Hard CVD Events
Overall, 256 hard CVD events (5%) (excluding angina leading to revascularization) occurred during 7.6 years of median follow-up. Those with any CAC accounted for 202 events (79%). Half of the events (128) occurred in the 21% of participants with CAC ≥100. Overall, the absolute incident hard CVD event rates were 1.8%, 5.3%, and 11.1% among those with CAC=0, CAC=1 to 99, and CAC ≥100, respectively. When follow-up duration was taken into account, the corresponding hard CVD event rates were 2.5 per 1000 person-years (95% CI, 1.9-3.3) for those with CAC=0 compared with 7.7 (95% CI, 6.1-9.6) and 16.9 (95% CI, 14.2-20.1) per 1000 person-years among those with CAC scores of 1 to 99 and ≥100, respectively.
Hazard ratios were attenuated but largely similar to the main results of all CVD events and remained statistically significant in the fully adjusted model for CAC ≥100 with the exception of the group with 3 LA (Table 3 ). In this group (n=330), the hazard ratio of 2.71 (95% CI, 0.80-9.13) was suggestive of inadequate power rather than a true absence of association. Indeed, results remained highly statistically significant in the highest TC/HDL-C quartile (n=1383) with a hazard ratio of 3.19 (95% CI, 1.60-6.36). In those with 0 LA or in the lowest TC/HDL-C quartile, CAC >0 and CAC ≥100 were significantly associated with hard CVD events in fully adjusted models.
Discussion
In multiethnic, asymptomatic, middle-aged to elderly men and women from the general community, our study examines 2 paradigms of risk assessment: dyslipidemia (risk factor) and CAC (measurable atherosclerosis). Evaluating interplay between the two, we show that many individuals with dyslipidemia have no CAC, whereas many individuals without dyslipidemia have CAC. We find that CAC stratifies CVD risk regardless of the burden of dyslipidemia and regardless of how dyslipidemia is defined. An event rate similar to that seen in secondary prevention populations (≥20 events per 1000 person-years) is estimated for patients with CAC ≥100 throughout the spectrum of dyslipidemia. In contrast, when CAC=0, absolute event rates remain relatively low across varying levels of dyslipidemia.
Allocating Statin Therapy: To Prevent Events, There Must Be Events
We focused on patients who were not on statin therapy at baseline but could have been considered for therapy. We do not propose that our single study can determine the proper management of any individual patient; however, this information is thought provoking and can help to guide discussions regarding the most optimal strategies to identify at-risk individuals. In the absence of data for years to come from a randomized clinical trial testing CAC in the allocation of statin therapy, it is important to consider that to prevent events, there must be events. The vast majority of events, at least over 7.6 years in MESA, occur in patients with CAC. So it is highly unlikely that clinical trial populations would have had enough events to demonstrate a benefit of statin therapy unless enriched with patients who had at least some CAC.
Normal Lipids But Detectable CAC
The term normal is often applied to lipids. Consistent with guidelines and clinical trials, we classified LDL-C of <3.36 mmol/L (130 mg/dL) as normal. It is important to recognize, however, that LDL-C of 3.36 mmol/L may be 2-to 3-fold higher than what is biologically normal or clinically ideal. 15 Relatively few individuals in the Western world have truly normal lipids. Therefore, it is no surprise that patients have consistently benefited from statin therapy in clinical trials regardless of the baseline lipid profile. 5 In individuals in our study without any dyslipidemia by traditional definitions, 1 in 5 had CAC ≥100, in which case absolute risk was high. Therefore, considering detectable subclinical atherosclerosis by CAC for such patients could help to weigh absolute risk more heavily in decision making, in agreement with the stated goal of guidelines. Although CAC itself is not generally modifiable with statin therapy, whereas dyslipidemia is, CAC may have the potential to give the clinician and patient a more reliable understanding of the probability of the patient having an event in the near future.
Dyslipidemia But CAC=0
Even in the presence of 3 LA, when CAC=0, the absolute event rate was <6% over 7.6 years and less than a third of the event rate in participants with 0 LA and CAC ≥100. However, some events do occur when CAC=0; CAC does not measure noncalcified plaques, and as a snapshot of information up to that point in time, CAC does not capture ongoing exposure to risk from dyslipidemia and other risk factors. We do not propose a single way to manage a middle-aged to elderly patient with dyslipidemia and CAC=0, but if treatment is instituted, we would submit that the discussion with the patient should specify that the primary treatment goal is to reduce long-term accumulation of atherosclerosis and not to reduce near-term events.
Estimating the Number Needed to Treat
To provide the most clinically relevant information, it may be useful to interpret these results in light of findings from statin trials to project an estimated risk reduction onto the MESA population across categories of lipid abnormalities and CAC scores. This extrapolation allows estimation of a 5-year number needed to treat (NNT 5 ) for LDL-C lowering by statins with the use of previously described methods.
18,21 If we apply the 30% relative risk reduction associated with a 1.00-mmol/L (39-mg/dL) reduction in LDL-C from a Cochrane meta-analysis of statin therapy in primary prevention, 17 the estimated NNT 5 across dyslipidemia categories in this MESA cohort ranges from 23 to 30 in those with CAC ≥100. The NNT 5 is 30 in participants with no LA and CAC ≥100, whereas the NNT 5 is 154 in those with 3 LA and CAC=0. Hazard ratios are for the presence of coronary artery calcium (CAC)/high CAC by number of lipid abnormalities or TC/HDL-C quartile; the reference group is CAC=0 within each dyslipidemia category. Model 1 is unadjusted; model 2, adjusted for age, sex, ethnicity, education, and Multi-Ethnic Study of Atherosclerosis site; and model 3, adjusted for model 2 variables plus hypertension, diabetes mellitus, smoking, body mass index, and family history. Atherosclerotic cardiovascular disease events included myocardial infarction, angina resulting in revascularization, resuscitated cardiac arrest, stroke, cardiovascular death. HDL-C indicates high-density lipoprotein cholesterol; and TC, total cholesterol. However, we caution that the risk reduction and NNT 5 with statin therapy, as extrapolated from efficacy demonstrated in randomized, controlled trials, may or may not reflect the actual effectiveness of statins in the MESA cohort and may or may not apply equally to the different subgroups in this study. In particular, CAC testing was not performed in the statin intervention trials, and therefore the meta-analyses have not assessed the efficacy of treatment across CAC subgroups.
Integrating Into the Framingham Approach
The Framingham Risk Score is an important paradigm in absolute risk assessment, and US guidelines 1,2 recommend it to synthesize risk from traditional risk factors. Multiple prior studies have shown the value of CAC in further refining absolute risk assessment beyond traditional risk factors or the Framingham Risk Score. [6] [7] [8] [9] In MESA participants classified as intermediate risk by the Framingham Risk Score, CAC provided superior discrimination and risk reclassification for incident coronary heart disease/CVD compared with other novel risk factors, including carotid intima-media thickness, ankle-brachial index, high-sensitivity C-reactive protein, and family history. 9 Adding CAC to the Framingham Risk Score yielded a net reclassification improvement of 0.466 for CVD events (net correct reclassification: 10.6% events; 36.0% nonevents).
Nevertheless, only 1% of women and 15% of men in the Dallas Heart Study were classified as intermediate risk by the Framingham Risk Score, and <0.1% and 1.1%, respectively, changed from intermediate to high risk with the use of a CAC threshold of ≥400. 22 An imaging strategy targeted at persons classified as low risk by the Framingham Risk Score was more efficient. Indeed, in a prior MESA study of women classified as low risk by the Framingham Risk Score, the prevalence of CAC >0 was 32%, and compared with women with no detectable CAC, there was an increased risk of CVD events (hazard ratio, 5.2; 95% CI, 2.5-10.8). 23 Overall, clinically integrating CAC assessment with global risk scores appears to supplement risk stratification and potentially identify appropriate candidates who may be more likely and less likely to benefit from established treatment strategies, such as statins. Further studies are needed to specifically define the optimal strategy for integrating CAC assessment into the Framingham approach.
Limitations
CAC has several potential limitations. First, image acquisition and interpretation add healthcare costs. Nevertheless, the cost is generally ≈$90, which is 18 months of therapy with a generic statin priced at $5 per month. Second, radiation exposure is required; the average measured dose of radiation was 0.89 mSv in MESA, whereas the dose with modern technology is as low as 0.5 mSv compared with background radiation of 3 mSv per year. Third, incidental noncardiac findings (eg, nodules) can generate recommendations for additional follow-up imaging in ≈5% of adults without a history of smoking, although some data suggest less downstream spending in those with CAC=0. 24 Our study itself also has potential limitations to consider. First, participants and their physicians were informed of their CAC score, which may have modified the use of preventive medical therapies during follow-up and cardiovascular event rates (particularly angina resulting in revascularization). Addressing these possible sources of bias, we performed sensitivity analyses examining the extent to which risk associated with CAC was sensitive to baseline and follow-up dyslipidemia Hazard ratios are for the presence of coronary artery calcium (CAC)/high CAC by number of lipid abnormalities and TC/HDL-C quartiles; the reference group is CAC=0 within each dyslipidemia category. Model 1 is unadjusted; model 2, adjusted for age, sex, ethnicity, education, and Multi-Ethnic Study of Atherosclerosis site; and model 3, adjusted for model 2 variables plus hypertension, diabetes mellitus, smoking, body mass index, and family history. Hard atherosclerotic cardiovascular disease events included myocardial infarction, resuscitated cardiac arrest, stroke, and cardiovascular death. HDL-C indicates high-density lipoprotein cholesterol; and TC, total cholesterol.
by guest on April 14, 2017 http://circ.ahajournals.org/ Downloaded from medications, as well as inclusion of angina resulting in revascularization in the combined CVD end point. In these analyses, the overall pattern of findings was largely similar to our main results. Finally, although our study was designed to examine risk stratification, we could not directly test whether incorporation of CAC into clinical decision making would translate into improved clinical outcomes and be cost-effective.
Conclusion
Measurable atherosclerosis by CAC appears to stratify CVD risk across the spectrum of dyslipidemia in asymptomatic middle-aged to elderly men and women from the general community. At the patient level, CAC may help to further "personalize" efforts to weigh expected benefits and costs of statin treatment, especially in patients with a history of side effects from statin treatment. At the population level, CAC may help to prioritize decisions about statin therapy in a costconstrained healthcare system, directing it to the patients at highest absolute risk, in accordance with the goal of worldwide clinical practice guidelines.
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